12 The study showed a significant trend in terms of older age distribution (median 59.3 years) and utilization of matched unrelated donors (45.2%) in more recent times. 12 The study also showed decreasing rates of acute and chronic graft- versus -host disease, with recent rates of extensive chronic graft- versus -host disease at 23%.
← all excerpts
Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
1
—
—